Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Edwards Lifesciences Co. (NYSE:EW) have been given an average rating of “Hold” by the twenty-six analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $79.19.

A number of equities research analysts recently weighed in on EW shares. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price target for the company from $82.00 to $90.00 in a report on Monday, December 16th. Barclays raised their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a report on Monday, December 2nd. Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target for the company. in a report on Thursday, January 16th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Finally, The Goldman Sachs Group lifted their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $72.41 on Monday. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average of $72.49 and a two-hundred day moving average of $69.85. The company has a market capitalization of $42.71 billion, a P/E ratio of 10.45, a P/E/G ratio of 3.65 and a beta of 1.11.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,000 shares of company stock valued at $2,195,180 over the last 90 days. 1.29% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several institutional investors have recently made changes to their positions in the stock. Algert Global LLC increased its holdings in shares of Edwards Lifesciences by 38.4% during the second quarter. Algert Global LLC now owns 4,616 shares of the medical research company’s stock worth $426,000 after buying an additional 1,280 shares in the last quarter. Centaurus Financial Inc. increased its holdings in shares of Edwards Lifesciences by 13.2% during the second quarter. Centaurus Financial Inc. now owns 1,822 shares of the medical research company’s stock worth $168,000 after buying an additional 212 shares in the last quarter. Czech National Bank increased its holdings in shares of Edwards Lifesciences by 6.9% during the third quarter. Czech National Bank now owns 122,715 shares of the medical research company’s stock worth $8,098,000 after buying an additional 7,883 shares in the last quarter. Harbor Investment Advisory LLC increased its holdings in shares of Edwards Lifesciences by 16.7% during the third quarter. Harbor Investment Advisory LLC now owns 16,383 shares of the medical research company’s stock worth $1,081,000 after buying an additional 2,339 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Edwards Lifesciences by 21.6% during the third quarter. GAMMA Investing LLC now owns 4,105 shares of the medical research company’s stock worth $271,000 after buying an additional 730 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.